Back to Hematology
Hematologyv2008Evidence-Based

HERDOO2 Rule for Discontinuing Anticoagulation in Unprovoked VTE

Identifies low-risk women who can safely discontinue anticoagulation after completing treatment for unprovoked venous thromboembolism (VTE). The rule helps clinicians decide which patients can stop anticoagulation therapy after the initial treatment period.

Clinical Input Parameters

Clinical Assessment
Awaiting Parameters
herdoo2 score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The HERDOO2 Rule for Discontinuing Anticoagulation in Unprovoked VTE is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Score = Post-thrombotic signs (1 point) + D-dimer ≥250 μg/L (1 point) + BMI ≥30 kg/m² (1 point) + Age ≥65 years (1 point)

Clinical Pearls & Practice Notes

  • Only applicable to women with first unprovoked VTE who have completed 5-12 months of anticoagulation
  • D-dimer should be measured while patient is still on anticoagulation
  • Not applicable to men or women with provoked VTE
  • Post-thrombotic signs include hyperpigmentation, edema, or redness in either leg

Evidence & Literature Citations

  1. Rodger MA, Kahn SR, Wells PS, Anderson DA, Chagnon I, Le Gal G, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008 Aug 26;179(5):417-26.
  2. Rodger MA, Le Gal G, Anderson DR, Schmidt J, Pernod G, Kahn SR, et al.; REVERSE II Study Investigators. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ. 2017 Mar 17;356:j1065.

Score Interpretation Ranges

Low Risk0 – 1 pts

Can discontinue anticoagulation

Not Low Risk2 – 4 pts

Continue anticoagulation

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.